Intravenous or oral topoisomerase I inhibitor formulation for small cell lung, ovarian, and cervical cancer treatments. Employed in comprehensive cancer centers and hospital oncology services. Procured from pharmaceutical distributors by healthcare buyers for use in recurrent or refractory malignancy protocols.